The actual prevalence was compared to the expected Hardy-Weinberg prevalence by chi-squared test. RESULTS The prevalence of the R820W mutation in ragdolls was 27% (25 center dot 6% heterozygous,
1 center dot 4% homozygous), and that of the A31P mutation in Maine coons was 39 center dot 4% (36 center dot 4% homozygous, 3% heterozygous). There were more female cats (69 center dot 5% ragdoll, 70 center dot 3% Maine coon). The median age was 6 center dot 4 months (ragdolls) and 5 center dot 9 months (Maine coons). Cats from more than 60 counties were represented for each breed. The difference between the expected and observed allele frequency NVP-BKM120 was significant in Maine P5091 molecular weight coons (P=0 center dot 047) but not in ragdolls (P=0 center dot 092). CLINICAL SIGNIFICANCE This is the
first report of prevalence and demographics of the R820W and A31P mutations in ragdolls and Maine coons, respectively, in the British Isles. The prevalence is high, which is of relevance for breeding and screening programmes. The significant difference in genetic distribution may suggest early death of homozygous Maine coons.”
“Background: Diabetes is a major cardiovascular risk factor. However, its influence on the rate of occurrence of cardiovascular (CV) events during a clinical trial that included a diabetes subgroup has not yet been quantified. Aims: To establish equations relating baseline diabetes prevalence and incident CV events, based on comparator arms data of major lipid-modifying trials. Methods: Meta-analysis of primary outcomes (PO) rates of key prospective trials, for which the baseline proportion of diabetics was reported, including studies having specifically reported CV outcomes within their diabetic subgroups. Results:
47 studies, representing 330,376 patients (among whom 124,115 diabetics), CH5424802 concentration were analyzed as regards the relationship between CV outcomes rates (including CHD) and the number of diabetics enrolled. Altogether, a total of 18,445 and 16,156 events occurred in the comparator and treatment arms, respectively. There were significant linear relationships between diabetes prevalence and both PO and CHD rates (%/year): y = 0.0299*x + 3.12 [PO] (p = 0.0128); and y = 0.0531*x + 1.54 [CHD] (p = 0.0094), baseline diabetes predicting PO rates between 3.12 %/year (no diabetic included) and 6.11 %/year (all patients diabetic); and CHD rates between 1.54 %/year (no diabetic) and 6.85 %/year (all patients diabetic). The slopes of the equations did not differ according to whether they were derived from primary or secondary prevention trials. Conclusions: Absolute and relative CV risk associated with diabetes at inclusion can be readily predicted using linear equations relating diabetes prevalence to primary outcomes or CHD rates.